力克菲蒺利福喷汀阿米卡星左氧氟沙星的方案doc.docVIP

“力克菲蒺、利福喷汀、阿米卡星、左氧氟沙星”方案 对肝损害肺结核疗效及安全性观察 林志来 施振慧 翁 恒 林友飞 陈力舟 林剑东 朱玉芳 （福建医科大学福州肺科医院临床教学医院 福州 350008） 摘要：〔目的〕 观察“力克肺疾、利福喷汀、阿米卡星、左氧氟沙星”方案对肝功损害肺结核的疗效及安全性。〔方法〕 对肝功损害肺结核100例采用随机配对分组法分为治疗组（50例）和对照组（50例）。化疗方案：治疗组用力克肺疾（D）、利福喷汀（L）、阿米卡星（K）、左氧氟沙星（V）；对照组用异烟肼（H）利福平（R）、阿米卡星（K）、吡嗪酰胺（Z），疗程均为9个月。〔结果〕 共有96例患者完成化疗程，治疗组49例和对照组47例，治疗9个月后治疗组涂阳阴转率为95.O％，培阳阴转率96.4％；对照组涂阳阴转率为94.4％，培阳阴转率95.7％。疗程结束时治疗组和对照组X线病灶有效率分别为98.0％和97.9％；空洞闭合率分别为61.5％和57.1％；2组在疗效上无显著性差异（P0.05）；2年复查，治疗组和对照组痰菌复阳率分别为3.7％和4.5％无显著性差异（P0.05）。2组肝功能损害治疗组为32.0%，对照组为58.0％，在肝损害上有显著性差异（P0.01）。〔结论〕 “DLKV”方案对肝功能损害肺结核疗效确切且较安全。 关键词：结核，肺／药物疗法；肝损害 Clinical observation on the clinical efficacy and safety of the regimen of‘Pasiniazid Rifapentine Amikacin and Levofloxcin’for lesions of the liver caused by tuberculosis Lin Zhilai，Shi Zhenhui，Weng Heng，et a1． Clinical Teaching Division of Fuzhou Pulmonary Hospital Affiliated to Fujian Medical University，Fuzhou 350008，China Abstract：Objective To observe the clinical efficacy and safety of the treatment regimen of‘Pasiniazid，Rifapentine,Amikacin and Levofloxcin’for lesions of the liver caused by tuberculosis．Methods By random group-matching 100 cases with lesions of the liver caused by tuberculosis were divided into the treatment group（50 cases） and gontrol group（50 cases）．The chemotherapy regimen adopted：the treatment group used Pasiniazid（D），Rifapentine（L），Amikacin（K） and Levofloxcin（V） while the control group used Isoniazid（H），Rifampein（R），Amikacin（K），and Pyrazinamide（Z）．The course of treatment was 9 1months for both groups．Results Ninty-siX cases completed the treatment with 49 cases in the treatment group and 47 cases in the control group. In the treatmentgroup，the sputum negative conversion rate by the end of the 9th month was 95.0％in smear and 96.4% in culture；while in the control group，the rates were 94.4％ and 95.7％respectively．At the end of the treatment,X-rays evidently improved the assimilation of focuses up to 98.0％in the treatment group and 97.9％ in the contr